Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP Study: Treating PWID with HCV in Community Settings
NCT02363517Phase 3Unknown
- Sponsor
- Burnet Institute
- Start
- Feb 2015
- Primary completion
- Dec 2018
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 3 trial of Harvoni in hepatitis C (HCV), sponsored by Burnet Institute. Status: unknown.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02363517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363517.